LT2002123A - Novel interferon for the treatment of multiple sclerosis - Google Patents

Novel interferon for the treatment of multiple sclerosis

Info

Publication number
LT2002123A
LT2002123A LT2002123A LT2002123A LT2002123A LT 2002123 A LT2002123 A LT 2002123A LT 2002123 A LT2002123 A LT 2002123A LT 2002123 A LT2002123 A LT 2002123A LT 2002123 A LT2002123 A LT 2002123A
Authority
LT
Lithuania
Prior art keywords
multiple sclerosis
treatment
ifn
biologically
novel interferon
Prior art date
Application number
LT2002123A
Other languages
English (en)
Lithuanian (lt)
Inventor
Edward M. Croze
Daryl Faulds
T. Charis Wagner
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of LT2002123A publication Critical patent/LT2002123A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
LT2002123A 2000-06-16 2002-12-02 Novel interferon for the treatment of multiple sclerosis LT2002123A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21204600P 2000-06-16 2000-06-16
US09/881,050 US20020025304A1 (en) 2000-06-16 2001-06-15 Novel interferon for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
LT2002123A true LT2002123A (en) 2003-06-25

Family

ID=26906704

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002123A LT2002123A (en) 2000-06-16 2002-12-02 Novel interferon for the treatment of multiple sclerosis

Country Status (22)

Country Link
US (1) US20020025304A1 (pl)
EP (1) EP1289541A2 (pl)
JP (1) JP2004505021A (pl)
KR (1) KR20030009529A (pl)
CN (1) CN1436086A (pl)
AU (1) AU2001267099A1 (pl)
BG (1) BG107370A (pl)
BR (1) BR0111852A (pl)
CA (1) CA2413077A1 (pl)
CZ (1) CZ20024094A3 (pl)
EE (1) EE200200693A (pl)
HU (1) HUP0300787A2 (pl)
IL (1) IL152996A0 (pl)
LT (1) LT2002123A (pl)
MX (1) MXPA02012308A (pl)
NO (1) NO20025964L (pl)
NZ (1) NZ522849A (pl)
PL (1) PL359562A1 (pl)
RU (1) RU2003100517A (pl)
SI (1) SI21080A (pl)
SK (1) SK17612002A3 (pl)
WO (1) WO2001095929A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1565205A4 (en) * 2002-11-18 2006-07-05 Maxygen Inc Interferon-alpha polypeptides and conjugates
EP1712992A1 (en) * 2005-04-11 2006-10-18 Sony Ericsson Mobile Communications AB Updating of data instructions
EP2536435B1 (en) 2010-02-18 2017-11-15 Janssen Biotech, Inc. Monkey homolog of human interferon omega
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
EP3743448A4 (en) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 BINDING AGENTS AND USES THEREOF
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
WO2024192373A1 (en) * 2023-03-16 2024-09-19 A-Alpha Bio Interferon alpha-2 variants
US12281147B2 (en) 2023-08-14 2025-04-22 A-Alpha Bio, Inc. Interleukin 21 variants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
HUT76099A (en) * 1994-05-10 1997-06-30 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis
EP1037995A1 (en) * 1997-12-08 2000-09-27 Genentech, Inc. Human interferon-epsilon: a type 1 interferon
SK17762000A3 (sk) * 1998-05-29 2001-07-10 Biogen, Inc. Farmaceutický prípravok obsahujúci rekombinantný ľudský interferón beta-1a
JP2002526078A (ja) * 1998-09-18 2002-08-20 ザイモジェネティクス，インコーポレイティド インターフェロン−イプシロン
AU2001255380A1 (en) * 2000-04-14 2001-10-30 Zymogenetics Inc. Human interferon, zinf2

Also Published As

Publication number Publication date
CZ20024094A3 (cs) 2003-05-14
AU2001267099A1 (en) 2001-12-24
PL359562A1 (pl) 2004-08-23
JP2004505021A (ja) 2004-02-19
HUP0300787A2 (hu) 2003-07-28
NO20025964D0 (no) 2002-12-12
WO2001095929A3 (en) 2002-10-10
CA2413077A1 (en) 2001-12-20
CN1436086A (zh) 2003-08-13
SK17612002A3 (sk) 2003-08-05
KR20030009529A (ko) 2003-01-29
WO2001095929A2 (en) 2001-12-20
BG107370A (en) 2003-11-28
EE200200693A (et) 2004-06-15
RU2003100517A (ru) 2004-06-27
BR0111852A (pt) 2003-05-20
EP1289541A2 (en) 2003-03-12
NO20025964L (no) 2003-02-14
SI21080A (sl) 2003-06-30
IL152996A0 (en) 2003-06-24
US20020025304A1 (en) 2002-02-28
MXPA02012308A (es) 2003-04-25
NZ522849A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
EP0662827A4 (en) THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON NOTCH PROTEINS AND NUCLEIC ACIDS.
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
HUP0004853A3 (en) Hepatitis c inhibitor peptides, process for preparation thereof, pharmaceutical compositions comprising thereof, their use and their intermediates
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
EP1033998A4 (en) METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER
BRPI9710372B8 (pt) composto, e, composição farmacêutica.
IL138665A0 (en) Peptide factor
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
IL136737A0 (en) Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
LT2002123A (en) Novel interferon for the treatment of multiple sclerosis
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
SI1082131T1 (en) Immunoregulator
EP1501936A4 (en) PROTEIN FAMILY OF CYTOKINE
DE69736276D1 (de) Menschliche dnase resistent gegen actininhibitoren
IL134263A0 (en) Use of phanquinone for the treatment of alzheimer's disease
CA2433785A1 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
IL145722A0 (en) Pharmaceutical composition comprising growth hormone and interferon
ATE371737T1 (de) Proteaseresistente flint-analoge
DK0938329T3 (da) Immunogen TLP sammensætning
HUT77422A (hu) Humán dezoxiribonukleáz I variánsok